Cross-sectional study examines treatment patterns and demographics in adult atopic dermatitis patients, suggesting differences between biologics and JAK inhibitors.
Key Points
This study highlights demographic and clinical differences in adult patients with atopic dermatitis initiating biologics or JAK inhibitors.
The analysis reported 1604 biologic initiations and 354 JAK inhibitor initiations, indicating treatment preferences.
Observational data was gathered from the CorEvitas atopic dermatitis registry over three years, providing a real-world perspective.
These findings suggest a need for further comparative studies to guide treatment decisions in atopic dermatitis management.